MCID: SRS001
MIFTS: 60

Serous Cystadenocarcinoma malady

Cancer diseases category

Summaries for Serous Cystadenocarcinoma

About this section


Disease Ontology:9 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary: Serous Cystadenocarcinoma, also known as serous cystadenocarcinoma, nos, is related to cystadenocarcinoma and ovarian serous cystadenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is BIRC5 (baculoviral IAP repeat containing 5), and among its related pathways are Ovarian Infertility Genes and Plasma membrane estrogen receptor signaling. The compounds tanshinone iia and toremifene have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and colon, and related mouse phenotypes are pigmentation and hearing/vestibular/ear.

Wikipedia:64 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. more...

Aliases & Classifications for Serous Cystadenocarcinoma

About this section
Sources:
9Disease Ontology, 11DISEASES, 44Novoseek, 61UMLS, 34MeSH, 39NCIt, 56SNOMED-CT
See all sources

Serous Cystadenocarcinoma, Aliases & Descriptions:

Name: Serous Cystadenocarcinoma 9 11
Serous Cystadenocarcinoma, Nos 9
Cystadenocarcinoma, Serous 61
 
Cystadenocarcinoma Serous 44
Serous Adenocarcinoma 9
Serous Carcinoma 9


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases


External Ids:

Disease Ontology9 DOID:3114
MeSH34 D018284
SNOMED-CT56 90725004, 189685001

Related Diseases for Serous Cystadenocarcinoma

About this section

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 162)
idRelated DiseaseScoreTop Affiliating Genes
1cystadenocarcinoma32.6MUC16
2ovarian serous cystadenocarcinoma31.6MUC16, ZNF217, UBE4A, USP2, USP14
3adenofibroma31.1MUC16
4bilateral breast cancer30.6ESR1, PGR
5leiomyosarcoma30.5TP53, MUC16, PGR
6lymphangioleiomyomatosis30.4PGR, ESR1
7angiomyolipoma30.3PGR, ESR1
8malignant mixed mullerian tumor30.2PGR, TP53
9leiomyoma30.2ESR2, PGR, CYP19A1, ESR1
10breast cancer30.1ESR2, CYP19A1, PGR, ESR1, AKT1
11endometriosis30.0ESR2, MUC16, PGR, VEGFA, CYP19A1, ESR1
12endometrial carcinoma29.9MUC16, BCL2, ESR1, TP53, ESR2, PGR
13transitional cell carcinoma29.9BIRC5, MUC16, TP53, CDKN1A
14astrocytoma29.7TP53, AKT1, VEGFA, CDKN1A
15adenocarcinoma29.5CDKN1A, VEGFA, TP53, PGR, ESR2, ESR1
16leukemia29.2AKT1, FAS, ESR2, BCL2, BIRC5, BAX
17melanoma28.9VEGFA, AKT1, TP53, FAS, CDKN1A, BCL2
18ovarian cancer28.5BAX, TP53, ESR2, BIRC5, BCL2, PGR
19ovarian serous carcinoma11.0
20pancreatic serous cystadenocarcinoma10.6
21cerebral meningioma10.5PGR
22pericardial effusion10.5MUC16
23pancreatitis10.5
24peritonitis10.5
25peritoneal mesothelioma10.4
26ovarian disease10.4CYP19A1, MUC16
27estrogen excess10.4PGR, CYP19A1
28endophthalmitis10.4VEGFA
29peritoneal serous adenocarcinoma10.4
30progesterone resistance10.4ESR1, PGR
31ovarian cyst10.3ESR2, MUC16, CYP19A1
32breast fibroadenoma10.3ESR1, PGR
33endocrine gland cancer10.3ESR1, CYP19A1
34sertoli cell tumor10.3CYP19A1, PGR
35uterine sarcoma10.3CYP19A1, ESR1
36cribriform carcinoma10.3ESR1, PGR
37meningioma10.3PGR, ESR1
38mammary paget's disease10.3PGR, ESR1
39primary peritoneal carcinoma10.3
40hepatitis10.3
41teratoma10.3
42cervical serous adenocarcinoma10.3
43uterine corpus serous adenocarcinoma10.3
44uterine ligament serous adenocarcinoma10.3
45fallopian tube serous adenocarcinoma10.3
46ovary serous adenocarcinoma10.3
47male breast cancer10.3PGR, ESR1
48cutaneous t cell lymphoma10.3BIRC5, FAS, BAX
49leiomyomatosis10.3PGR, ESR1
50adenosarcoma10.3PGR, ESR1

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to serous cystadenocarcinoma

Symptoms for Serous Cystadenocarcinoma

About this section

Drugs & Therapeutics for Serous Cystadenocarcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Serous Cystadenocarcinoma

Search NIH Clinical Center for Serous Cystadenocarcinoma

Genetic Tests for Serous Cystadenocarcinoma

About this section

Anatomical Context for Serous Cystadenocarcinoma

About this section

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

32
Ovary, Pancreas, Colon, Breast, Bone, Lymph node, Spleen, Liver, Testis

Animal Models for Serous Cystadenocarcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

36 (show all 27)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.4BCL2, FAS, TP53, CYP19A1
2MP:00053779.2CYP19A1, ESR2, FAS, BCL2, BAX, CDKN1A
3MP:00053758.9CYP19A1, TP53, ESR2, ESR1, AKT1, BCL2
4MP:00053718.6VEGFA, TP53, PGR, ESR2, ESR1, FAS
5MP:00053708.6CYP19A1, VEGFA, TP53, ESR2, ESR1, FAS
6MP:00053918.5VEGFA, TP53, FAS, BCL2, BAX, CDKN1A
7MP:00028738.5PPP2R1A, CYP19A1, VEGFA, TP53, PGR, ESR2
8MP:00053818.5VEGFA, TP53, ESR2, ESR1, FAS, BCL2
9MP:00053888.4VEGFA, TP53, ESR2, ESR1, FAS, AKT1
10MP:00020068.2PPP2R1A, VEGFA, TP53, PGR, ESR2, ESR1
11MP:00053678.1USP2, VEGFA, TP53, ESR2, ESR1, FAS
12MP:00053808.1VEGFA, TP53, PGR, NANOG, ESR1, AKT1
13MP:00053977.8CYP19A1, VEGFA, TP53, PGR, ESR2, ESR1
14MP:00030127.8USP2, VEGFA, TP53, PGR, NANOG, ESR2
15MP:00053877.8ESR2, PGR, TP53, VEGFA, CYP19A1, ESR1
16MP:00053857.7CYP19A1, USP2, VEGFA, TP53, PGR, ESR2
17MP:00053797.6CYP19A1, USP2, VEGFA, TP53, PGR, ESR2
18MP:00053907.5TP53, VEGFA, USP14, CYP19A1, PGR, ESR2
19MP:00053697.5TP53, VEGFA, USP14, CYP19A1, PGR, ESR2
20MP:00107717.4TP53, VEGFA, USP14, CYP19A1, PGR, ESR2
21MP:00036317.3CYP19A1, USP14, VEGFA, TP53, ESR2, ESR1
22MP:00053787.1TP53, VEGFA, USP14, CYP19A1, PPP2R1A, ESR2
23MP:00053896.7CDKN1A, CYP19A1, USP14, USP2, VEGFA, TP53
24MP:00053866.4TP53, VEGFA, USP2, USP14, CYP19A1, PPP2R1A
25MP:00053846.4NANOG, PGR, TP53, VEGFA, USP14, CYP19A1
26MP:00107686.3NANOG, PGR, TP53, VEGFA, USP14, PPP2R1A
27MP:00053766.2TP53, VEGFA, USP2, USP14, CYP19A1, PPP2R1A

Publications for Serous Cystadenocarcinoma

About this section

Articles related to Serous Cystadenocarcinoma:

(show top 50)    (show all 90)
idTitleAuthorsYear
1
Paratesticular papillary serous cystadenocarcinoma: A rare entity in Indian population. (25308020)
2014
2
Neoplasms in the trocar site and peritoneal papillary serous cystadenocarcinoma. (25017255)
2014
3
IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. (24595078)
2013
4
Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. (23370947)
2013
5
Serous cystadenocarcinoma of pancreas. (23763806)
2013
6
Ovarian serous cystadenocarcinoma metastasising to the breast. (23445161)
2013
7
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. (23040941)
2012
8
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. (22400805)
2012
9
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. (22066125)
2011
10
Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. (20163045)
2009
11
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. (18818939)
2009
12
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. (19459016)
2009
13
Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. (19564753)
2009
14
Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. (19060596)
2008
15
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
16
Paratesticular papillary serous cystadenocarcinoma--a case report. (16625973)
2006
17
Serous cystadenocarcinoma of the pancreas: management of a rare entity. (16025006)
2005
18
Primary papillary serous cystadenocarcinoma of broad ligament. (15845057)
2005
19
Mean nuclear volume in ovarian papillary serous cystadenocarcinoma. (15032078)
2004
20
Plasma cell leukaemia with papillary serous cystadenocarcinoma of ovary--a case report. (15025299)
2003
21
Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. (12068151)
2002
22
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
23
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. (11516810)
2001
24
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
25
Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary. (9642449)
1998
26
Serous cystadenocarcinoma and ovarian teratoma during pregnancy. (8737305)
1996
27
Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. (8774651)
1996
28
Serous cystadenocarcinoma of the pancreas. (8968870)
1996
29
Morphologic criteria for the prognosis of serous cystadenocarcinoma of the ovary. (7737584)
1995
30
Stage III papillary serous cystadenocarcinoma of the ovary in a 15-year-old female. (8188094)
1994
31
Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. (9205465)
1994
32
Heterophile antigens in serous cystadenocarcinoma of the human ovary. (1283511)
1992
33
A rare case of serous cystadenocarcinoma of the pancreas. (1568167)
1992
34
Successful pregnancy after conservative surgery for ovarian papillary serous cystadenocarcinoma of low malignant potential. (1785199)
1991
35
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
36
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (2482644)
1989
37
Primary tumor of the rectovaginal septum: mesothelioma or papillary serous cystadenocarcinoma. A case report with transmission electron microscopy. (3668422)
1987
38
An amylase-producing serous cystadenocarcinoma of the ovary. (2409494)
1985
39
Serous cystadenocarcinoma as incidental finding during a repeat cesarean section. (4037003)
1985
40
Cytogenetics of a cell line derived from an ovarian papillary serous cystadenocarcinoma. (6744227)
1984
41
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (6206939)
1984
42
Occurrence of bone in serous cystadenocarcinoma of the ovary. (6816209)
1982
43
Mixed Mullerian tumour of ovary in association with breast carcinoma and serous cystadenocarcinoma carcinoma of other ovary. (6273302)
1981
44
Nature of carcinoembryonic antigen purified from malignant ascitic fluid of serous cystadenocarcinoma of the ovary. (7300840)
1981
45
Classification and survival rate of patients with serous cystadenocarcinoma of the ovaries. (1004656)
1976
46
An immunologic comparison between serous cystadenocarcinoma of the ovary and other human gynecologic tumors. (4126800)
1973
47
Immunologic studies of human serous cystadenocarcinoma of ovary. Demonstration of tumor-associated antigens. (4632680)
1973
48
Hypoglycemia associated with serous cystadenocarcinoma of the ovary. (4189963)
1970
49
Ultrastructure of ovarian tumors. I. Papillary serous cystadenocarcinoma. (4910128)
1970
50
Disseminated endosalpingiosis associated with bilateral papillary serous cystadenocarcinoma of the ovaries. A case report. (13909448)
1962

Variations for Serous Cystadenocarcinoma

About this section

Expression for genes affiliated with Serous Cystadenocarcinoma

About this section
Expression patterns in normal tissues for genes affiliated with Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Pathways for genes affiliated with Serous Cystadenocarcinoma

About this section

Pathways related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 90)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.8ESR2, PGR, CYP19A1
29.8AKT1, ESR1, ESR2
3
Show member pathways
9.8TP53, CDKN1A
49.8AKT1, BCL2, BAX
5
Show member pathways
9.8ESR2, ESR1, CYP19A1
6
Show member pathways
9.8BAX, FAS, BCL2
79.8AKT1, ESR1, BCL2
89.7BIRC5, AKT1, TP53
99.6BIRC5, AKT1, BCL2, BAX
10
Show member pathways
FAS pathway and Stress induction of HSP regulation37
Apoptosis and survival FAS signaling cascades59
Caspase cascade in apoptosis37
9.6BAX, FAS, BCL2, AKT1
119.5BAX, BCL2, ESR1, ESR2
12
Show member pathways
IL23-mediated signaling events37
Immune response IL 10 signaling pathway59
Angiopoietin receptor Tie2-mediated signaling37
Development PDGF signaling via STATs and NF kB59
Development Angiopoietin Tie2 signaling59
9.5BIRC5, BCL2, CDKN1A, AKT1
13
Show member pathways
9.5PPP2R1A, AKT1, BCL2, BAX
14
Show member pathways
9.5BCL2, BAX, AKT1, TP53
15
Show member pathways
Prostate Cancer37
Integrated Cancer pathway37
Steroid Biosynthesis37
9.5BCL2, BAX, AKT1, TP53
16
Show member pathways
9.5BCL2, AKT1, BAX, TP53
17
Show member pathways
Cell cycle ESR1 regulation of G1 S transition59
Immune response MIF JAB1 signaling59
Cell cycle Cell cycle generic schema 59
9.4CDKN1A, PGR, AKT1, ESR1
189.4CDKN1A, BCL2, AKT1, VEGFA
199.4AKT1, TP53, BAX, CDKN1A
20
Show member pathways
Immune response IL 4 signaling pathway59
Signal transduction AKT signaling59
9.4TP53, BAX, CDKN1A, AKT1
21
Show member pathways
DNA damage response37
9.4CDKN1A, BAX, FAS, TP53
22
Show member pathways
Prolactin Signaling Pathway37
Development Prolactin receptor signaling59
Leptin signaling pathway37
9.3ESR2, ESR1, BCL2, BAX, AKT1
239.3BAX, TP53, BCL2, CDKN1A
24
Show member pathways
9.3BAX, BCL2, TP53, CDKN1A
25
Show member pathways
9.3CDKN1A, VEGFA, TP53, AKT1
269.3AKT1, CDKN1A, TP53, PPP2R1A
279.3CDKN1A, VEGFA, TP53, BCL2
28
Show member pathways
9.2BCL2, TP53, AKT1, BAX, FAS
29
Show member pathways
Apoptosis and survival TNFR1 signaling pathway59
TWEAK Signaling Pathway37
Apoptosis Modulation by HSP7037
HIV-1 Nef- Negative effector of Fas and TNF-alpha37
9.2BAX, FAS, AKT1, BCL2, TP53
309.2TP53, CDKN1A, BAX, AKT1, BIRC5
319.1CDKN1A, BCL2, FAS, BAX, TP53
32
Show member pathways
Signaling Pathways in Glioblastoma37
9.1CDKN1A, TP53, AKT1, BCL2, VEGFA
33
Show member pathways
9.0AKT1, TP53, FAS, BCL2, BIRC5, BAX
34
Show member pathways
Apoptosis Modulation and Signaling37
Apoptosis37
9.0BCL2, BAX, BIRC5, AKT1, FAS, TP53
35
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor37
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
9.0BAX, BCL2, TP53, AKT1, FAS, ESR1
36
Show member pathways
Signal transduction PTEN pathway59
9.0CDKN1A, TP53, AKT1, BCL2, BIRC5, BAX
37
Show member pathways
Apoptosis and survival Apoptotic TNF family pathways59
8.9BIRC5, BCL2, FAS, TP53, BAX, CDKN1A
38
Show member pathways
8.9BAX, CDKN1A, BCL2, AKT1, FAS, TP53
39
Show member pathways
8.8TP53, AKT1, BAX, BCL2, CDKN1A, PPP2R1A
408.8TP53, CDKN1A, PPP2R1A, VEGFA, AKT1, BCL2
418.7VEGFA, BAX, BCL2, CYP19A1, ESR1, TP53
42
Show member pathways
Proteasome Degradation37
Immune response Antigen presentation by MHC class I59
8.6AKT1, TP53, BAX, BCL2, PPP2R1A, FAS
438.4VEGFA, TP53, FAS, AKT1, BCL2, BIRC5
44
Show member pathways
Toll-like receptor signaling pathway37
Regulation of toll-like receptor signaling pathway37
8.4CDKN1A, BAX, AKT1, TP53, PPP2R1A, BIRC5
45
Show member pathways
8.4AKT1, ESR1, ESR2, PPP2R1A, CDKN1A, TP53
46
Show member pathways
8.4ESR1, ESR2, PPP2R1A, CDKN1A, BCL2, AKT1
47
Show member pathways
8.3VEGFA, PPP2R1A, CDKN1A, BAX, BCL2, AKT1
48
Show member pathways
DNA damage response (only ATM dependent)37
Wnt Signaling Pathway and Pluripotency37
8.2NANOG, TP53, PPP2R1A, AKT1, CDKN1A, BCL2
498.2ESR1, CDKN1A, AKT1, FAS, VEGFA, NANOG
508.2BCL2, BAX, CDKN1A, ESR1, ESR2, TP53

Compounds for genes affiliated with Serous Cystadenocarcinoma

About this section

Compounds related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 245)
idCompoundScoreTop Affiliating Genes
1tanshinone iia449.7BCL2, BAX, TP53, FAS
2toremifene44 1210.6FAS, ESR1, ESR2, PGR, CYP19A1
3hoechst 33342449.5BAX, CDKN1A, BCL2, FAS, BIRC5
4trastuzumab44 50 1211.3CYP19A1, VEGFA, FAS, ESR1, BIRC5, PGR
5noxa449.3BAX, CDKN1A, FAS, TP53, BCL2, BIRC5
6suberoylanilide hydroxamic acid449.3TP53, CDKN1A, BAX, BIRC5, BCL2, FAS
73,3-diindolylmethane449.3BAX, BIRC5, ESR1, TP53, VEGFA, CDKN1A
8mifepristone44 29 60 1212.2VEGFA, CYP19A1, ESR1, ESR2, BIRC5, BAX
9cd 437449.2CDKN1A, BCL2, FAS, TP53, BAX
10n-(4-hydroxyphenyl)retinamide449.2ESR1, BCL2, BAX, CDKN1A, CYP19A1, TP53
11celecoxib44 60 29 50 25 1214.2CYP19A1, AKT1, BCL2, BIRC5, VEGFA, BAX
12flavopiridol44 1210.2VEGFA, BIRC5, BAX, CDKN1A, TP53, BCL2
13gefitinib44 50 1211.2ESR1, ESR2, VEGFA, CDKN1A, BIRC5, AKT1
142-chlorodeoxyadenosine449.1FAS, TP53, BCL2, BIRC5, BAX
15bortezomib44 50 1211.1VEGFA, TP53, BCL2, BAX, CDKN1A, BIRC5
16adpribose449.0BCL2, FAS, TP53, BAX, BIRC5, CDKN1A
17sp 60012544 609.9BCL2, AKT1, BAX, CDKN1A, TP53, FAS
18indole-3-carbinol448.9CDKN1A, BAX, BIRC5, BCL2, AKT1, ESR1
19curcumin448.9TP53, BAX, AKT1, BCL2, BIRC5, CDKN1A
20adriamycin448.9PGR, FAS, AKT1, BIRC5, TP53, BCL2
21etoposide44 50 60 1211.9ESR2, FAS, BCL2, BIRC5, BAX, TP53
22gemcitabine44 50 1210.9BAX, BCL2, CDKN1A, CYP19A1, BIRC5, TP53
23thymidylate448.9BAX, FAS, CDKN1A, VEGFA, BCL2, TP53
24egcg448.8VEGFA, TP53, ESR2, FAS, BCL2, BIRC5
25geldanamycin44 50 60 1211.8VEGFA, TP53, PGR, ESR1, BIRC5, CDKN1A
26butyrate448.8CDKN1A, BAX, BCL2, AKT1, FAS, CYP19A1
27taxane448.8CDKN1A, BIRC5, ESR1, PGR, CYP19A1, TP53
28n acetylcysteine448.8TP53, BAX, FAS, AKT1, VEGFA, BCL2
29sb 20358044 609.8VEGFA, AKT1, CDKN1A, BIRC5, TP53, FAS
30cyclophosphamide44 50 1210.7BCL2, MUC16, CYP19A1, VEGFA, TP53, PGR
31arsenite44 259.7BAX, BIRC5, BCL2, AKT1, FAS, PGR
32mg 13244 609.6CDKN1A, BAX, BIRC5, BCL2, AKT1, FAS
33docetaxel44 50 60 1211.6CYP19A1, BIRC5, BCL2, ESR1, PGR, TP53
34ly294002448.5BAX, CDKN1A, BCL2, BIRC5, FAS, VEGFA
35actinomycin d448.4TP53, ESR2, FAS, AKT1, BCL2, BIRC5
36resveratrol44 60 25 1211.4BIRC5, ESR1, ESR2, PGR, TP53, VEGFA
375fluorouracil448.3BIRC5, BAX, CDKN1A, BCL2, FAS, CYP19A1
38retinoid448.3ESR1, BCL2, ESR2, CDKN1A, PGR, TP53
39genistein44 29 60 3 25 1213.3CDKN1A, BAX, BIRC5, BCL2, AKT1, FAS
40h2o2448.3ESR2, BAX, MUC16, TP53, FAS, AKT1
41progesterone44 29 60 25 1212.2ESR2, TP53, CYP19A1, PGR, ESR1, MUC16
42cisplatin44 50 60 1211.2BCL2, BIRC5, BAX, CDKN1A, FAS, MUC16
43retinoic acid44 259.2FAS, ESR1, ESR2, PGR, TP53, CYP19A1
44tamoxifen44 50 29 1211.0BCL2, BIRC5, BAX, CDKN1A, AKT1, CYP19A1
45cycloheximide448.0TP53, PGR, ESR2, ESR1, FAS, AKT1
46paraffin447.8VEGFA, CDKN1A, BAX, BCL2, AKT1, MUC16
47paclitaxel44 50 129.7CYP19A1, VEGFA, TP53, PGR, ESR1, MUC16
48estrogen447.7ESR2, ESR1, PGR, AKT1, BCL2, BIRC5
49doxorubicin44 50 129.5ESR2, BAX, CDKN1A, BIRC5, BCL2, PGR
50vegf447.2FAS, MUC16, ESR1, ESR2, PGR, TP53

GO Terms for genes affiliated with Serous Cystadenocarcinoma

About this section

Cellular components related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:04693010.0BCL2, BAX
2mitochondrial outer membraneGO:0057419.8BAX, BCL2, PGR
3membraneGO:0160208.9PPP2R1A, CYP19A1, VEGFA, ESR1, BCL2
4cytosolGO:0058298.3PPP2R1A, TP53, FAS, AKT1, BCL2, BIRC5
5nucleoplasmGO:0056547.5CDKN1A, RSF1, TP53, PGR, NANOG, ESR2
6nucleusGO:0056346.4NANOG, TP53, USP2, RSF1, PPP2R1A, ESR2

Biological processes related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 55)
idNameGO IDScoreTop Affiliating Genes
1activation-induced cell death of T cellsGO:00692410.4FAS, AKT1
2regulation of nitrogen utilizationGO:00680810.4BAX, BCL2
3transformed cell apoptotic processGO:00692710.4FAS, BAX
4regulation of protein homodimerization activityGO:04349610.4BAX, BCL2
5regulation of protein heterodimerization activityGO:04349710.4BAX, BCL2
6endoplasmic reticulum calcium ion homeostasisGO:03246910.4BAX, BCL2
7uterus developmentGO:06006510.4ESR2, ESR1
8renal system processGO:00301410.4FAS, BCL2
9response to acidGO:00110110.3BAX, BCL2
10B cell lineage commitmentGO:00232610.3BCL2, TP53
11positive regulation of nitric-oxide synthase activityGO:05100010.2ESR1, AKT1
12vagina developmentGO:06006810.2ESR1, ESR2, BAX
13positive regulation of protein oligomerizationGO:03246110.2BAX, TP53
14negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:04315410.2VEGFA, BIRC5, AKT1
15extrinsic apoptotic signaling pathway via death domain receptorsGO:00862510.2FAS, BCL2, BAX
16extrinsic apoptotic signaling pathway in absence of ligandGO:09719210.2FAS, BCL2, BAX
17positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:200124110.2FAS, PPP2R1A, BAX
18regulation of mitochondrial membrane permeabilityGO:04690210.1BCL2, TP53
19response to salt stressGO:00965110.1TP53, BAX
20positive regulation of peptidyl-serine phosphorylationGO:03313810.1AKT1, VEGFA, BCL2
21mitotic cell cycle arrestGO:07185010.1CDKN1A, TP53
22mammary gland alveolus developmentGO:06074910.1ESR1, VEGFA
23positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathwayGO:190074010.1AKT1, BCL2, TP53
24release of cytochrome c from mitochondriaGO:00183610.1TP53, BCL2, BAX
25positive regulation of sequence-specific DNA binding transcription factor activityGO:05109110.1ESR1, AKT1, ESR2
26response to gamma radiationGO:01033210.1TP53, BCL2, BAX
27negative regulation of autophagyGO:01050710.1BCL2, AKT1
28positive regulation of intrinsic apoptotic signaling pathwayGO:200124410.1BAX, BCL2, TP53
29neuron apoptotic processGO:05140210.1TP53, BCL2, BAX
30response to ischemiaGO:00293110.0BCL2, TP53
31negative regulation of apoptotic signaling pathwayGO:200123410.0BCL2, BAX
32cellular response to organic substanceGO:07131010.0BAX, BCL2
33negative regulation of gene expressionGO:01062910.0CDKN1A, ESR1, PGR
34cellular response to glucose starvationGO:04214910.0BCL2, TP53
35ovarian follicle developmentGO:00154110.0BAX, VEGFA, ESR2, BCL2
36response to toxic substanceGO:0096369.9FAS, BCL2, BAX, CDKN1A
37androgen metabolic processGO:0082099.9CYP19A1, ESR1
38cellular response to hypoxiaGO:0714569.8VEGFA, AKT1, TP53, BCL2
39positive regulation of apoptotic processGO:0430659.8BAX, AKT1, TP53, FAS
40protein complex assemblyGO:0064619.8FAS, TP53, PPP2R1A
41positive regulation of blood vessel endothelial cell migrationGO:0435369.7AKT1, VEGFA
42intrinsic apoptotic signaling pathwayGO:0971939.6AKT1, BCL2, TP53, BAX, CDKN1A
43positive regulation of mitotic cell cycleGO:0459319.6NANOG, USP2, BIRC5
44gene expressionGO:0104679.6AKT1, ESR2, PGR, PPP2R1A, ESR1
45negative regulation of cell growthGO:0303089.5CDKN1A, BCL2, ESR2, PPP2R1A, TP53
46apoptotic processGO:0069159.2FAS, BAX, BIRC5, AKT1, TP53, PPP2R1A
47negative regulation of apoptotic processGO:0430669.1BIRC5, TP53, FAS, AKT1, VEGFA, BCL2
48positive regulation of transcription from RNA polymerase II promoterGO:0459449.0AKT1, ESR1, TP53, VEGFA, NANOG
49negative regulation of transcription from RNA polymerase II promoterGO:0001228.9ESR2, USP2, VEGFA, TP53, NANOG
50regulation of transcription, DNA-templatedGO:0063558.7ESR1, ZNF217, TP53, NANOG, ESR2, PPP2R1A

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:03405610.2ESR1, ESR2
2BH3 domain bindingGO:05143410.2BAX, BCL2
3estrogen receptor activityGO:03028410.2ESR1, ESR2
4nitric-oxide synthase regulator activityGO:03023510.1ESR1, AKT1
5channel activityGO:01526710.1BAX, BCL2
6steroid bindingGO:00549610.0ESR1, ESR2, PGR
7steroid hormone receptor activityGO:00370710.0PGR, ESR2, ESR1
8core promoter sequence-specific DNA bindingGO:0010469.9ESR1, ESR2
9cyclin bindingGO:0303329.6CDKN1A, USP2
10protein phosphatase 2A bindingGO:0517219.6BCL2, TP53
11enzyme bindingGO:0198999.3TP53, PGR, ESR2, ESR1, AKT1, BIRC5
12protein heterodimerization activityGO:0469829.2PPP2R1A, VEGFA, TP53, BCL2, BIRC5, BAX
13zinc ion bindingGO:0082708.7RSF1, TP53, PGR, ESR2, ESR1, BIRC5
14identical protein bindingGO:0428028.3USP2, VEGFA, TP53, ESR1, FAS, AKT1
15protein bindingGO:0055154.6CDKN1A, PPP2R1A, RSF1, USP14, USP2, VEGFA

Products for genes affiliated with Serous Cystadenocarcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Serous Cystadenocarcinoma

About this section
4CDC
14ExPASy
15FMA
23GTR
24HGMD
25HMDB
26ICD10
27ICD10 via Orphanet
28ICD9CM
29IUPHAR
30KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet